Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab and Relatlimab in Resectable Cutaneous Squamous Cell Carcinoma
NCT06288191Phase 2Recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Jun 2024
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, relatlimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Melanoma Institute Australia. Started Jun 2024; status: recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06288191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06288191.